...
首页> 外文期刊>Asian Pacific Journal of Cancer Prevention >Clinical Observations on Treatment for Chinese Patients with Gastrointestinal Stromal Tumors
【24h】

Clinical Observations on Treatment for Chinese Patients with Gastrointestinal Stromal Tumors

机译:胃肠道肿瘤患者治疗临床观察

获取原文

摘要

Background: To investigate the diagnostic and treatment methods for Chinese patients with gastrointestinal stromal tumor (GIST). Materials and Methods: From January 2004 to June 2014, patients diagnosed with primary GIST and treated by a single medical team in the Department of Digestive Disease of XuYi Hospital of Traditional Chinese Medicine were retrospectively recruited. Re-examination and follow-up was conducted regularly and abdominal enhanced CT, blood biochemistry and responses to surgery or imatinib were recorded. Results: A total of 15 patients were enrolled, including 9 male and 6 female patients, with an average age of 54 years (ranging from 32-81 years). The primary symptoms were abdominal uncomfortable in 5 patients, abdominal pain in 6 patients as well as nausea and vomiting in 4 patients. One patient was diagnosed with bowl obstruction at the first visit. All patients were treated with surgery, and tumor site was confirmed 1 esophagus, 6 stomach, 4 small bowel, and 4 colorectal and all patients were pathologically diagnosed with GIST. Immunochemical test positive for CD 117 was found 12 patients, and positive for CD 34 in7 patients. The median follow-up time was 24 months (range of 3-63). Three metastasis were confirmed 1.5, 2 and 2.6 years postoperatively. Three patients were treatment by imatinib postoperatively. Conclusions: Surgery remains the main treatment method for Chinese patients with GIST and imatinib could be feasible and safe for treating Chinese patients with GIST.
机译:背景:探讨中国胃肠道肿瘤患者(GIST)的诊断和治疗方法。材料和方法:从2004年1月到2014年6月,追溯招聘患者诊断出患有原发性要素并由单一医学团队治疗的中医院消化系统中医院治疗。经常进行重新检查和随访,并记录腹部增强的CT,血液生物化学和对手术或伊马替尼的反应。结果:共有15名患者,包括9名男性和6名女性患者,平均为54岁(32-81岁)。 5名患者的腹部腹部腹部不舒服,6名患者的腹痛以及4名患者的恶心和呕吐。在第一次访问时诊断出一名患者患有碗障碍物。所有患者均用手术治疗,肿瘤部位确认1食管,6胃,4个小肠和4种成分,所有患者都病于GIST。发现CD 117的免疫化学测试阳性12名患者,CD 34 IN7患者阳性。中位后续时间为24个月(3-63的范围)。术后三种转移1.5,2和2.6岁。术后三名患者由伊马替尼治疗。结论:手术仍然是中国患有GIST和伊马替尼患者的主要治疗方法,可对治疗中国的患者可行和安全。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号